This phase II clinical trial is evaluating whether adding KRC-01 injections to standard chemoradiotherapy may improve treatment outcomes in patients with locally advanced rectal cancer without metastases.
KRC-01 is an investigational product designed to improve the effectiveness of radiotherapy by increasing oxygen levels inside tumors, which may help radiation work better. KRC-01 contains hydrogen peroxide and sodium hyaluronate and is injected directly into the tumor before radiotherapy sessions.
Previous clinical experience in Japan, including studies in several types of cancer, suggested that this approach may improve tumor oxygenation and enhance the effect of radiotherapy.
The main objective of the K-BOOST study is to evaluate how many patients achieve a complete clinical response after treatment with chemoradiotherapy combined with intratumoral KRC-01 injections, potentially allowing some patients to avoid surgery. Surgery may still be recommended depending on the individual response to treatment.
Approximately 24 patients will participate in this multicenter French study. The experimental treatment period lasts approximately 26 weeks, and participants will be followed for up to 2 years.

Start Date01 Jul 2026

Sponsor / Collaborator

Gustave Roussy, Cancer Campus, Grand Paris

[+1]

CTIS2025-524378-40-00

/ Not yet recruitingPhase 2IIT

Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach (K-BOOST)

Start Date28 May 2026

Sponsor / Collaborator

Institut Gustave Roussy EURL

NCT07534865

/ RecruitingNot ApplicableIIT

A Randomized, Parallel-Group, Controlled, Assessor-Blinded Clinical Trial of Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts

Hyperthermia treatment (hyperthermia) refers to treating diseases with temperature (39-45 ° C) beyond normal body temperature,. It has been reported that local warming at 44 ° C is able to effectively mobilize the body's immunity and clear HPV infected lesions, such as condyloma acuminatum and verruca vulgaris, etc. Significant progress has been made in the application of hyperthermia for viral skin diseases. Clinically, the addition of hydrogen peroxide solution can enhance the efficacy of hyperthermia in treating HPV infection. As a common transdermal drug delivery method, microneedles can increase drug penetration and thereby further improve treatment outcomes. Based on these findings, this study aims to explore an adjunctive approach to hyperthermia for treating viral warts to further enhance therapeutic efficacy.
This study employs a randomized, parallel-group, assessor-blinded design. Participants will be randomly assigned to three groups: hyperthermia alone, hyperthermia combined with microneedle patch (loaded with 0.9% saline), and hyperthermia combined with hydrogen peroxide microneedle patch (experimental group). An adaptive design will be adopted. The sample size is estimated at 70 participants per group, accounting for a potential 20% dropout rate. Interim analyses will be conducted during follow-up, and enrollment will be stopped when a positive result is reached for the primary efficacy endpoint (cure rate), at which point the sample size will be adjusted accordingly.

Start Date01 May 2026

Sponsor / Collaborator

The First Hospital Of China Medical University

100 Clinical Results associated with Hydrogen Peroxide

100 Translational Medicine associated with Hydrogen Peroxide

100 Patents (Medical) associated with Hydrogen Peroxide

182,224

Literatures (Medical) associated with Hydrogen Peroxide

01 Sep 2026·Infection Disease & Health

Comparative efficacy of preprocedural mouthwashes in reducing microbial aerosols during dental procedures: A network meta-analysis

Review

Author: Xiao, Yang ; Lin, Yuwei ; Li, Enhong ; Yu, Xuefen ; Hong, Feiruo ; Zhou, Qiuyu

BACKGROUND:

This study aimed to evaluate and rank the efficacy of common preprocedural mouthwashes in reducing microbial aerosols during dental procedures via network meta-analysis (NMA) and provide evidence-based guidance for clinical infection control.

METHODS:

We systematically searched eight electronic databases from inception to February 2025. Randomized controlled trials (RCTs) assessing mouthwashes for reducing microbial aerosols during dental procedures were included. A Bayesian NMA with a random-effects model was performed. Risk of bias was assessed using the Cochrane tool, and the certainty of evidence was evaluated using the CINeMA framework. Surface under the cumulative ranking curve (SUCRA) and standardized mean difference (SMD) with 95% confidence interval (CI) were calculated to quantify intervention effects.

RESULTS:

Twenty-five RCTs involving 1111 participants and eight interventions were included. Compared with the control group, chlorhexidine (CHX) showed the largest effect (SMD = -7.10, 95% CI [-9.44, -4.73]), followed by herbal mouthwash (SMD = -5.16, 95% CI [-8.04, -2.17]) and povidone-iodine (PVP-I) (SMD = -4.57, 95% CI [-8.79, -0.21]). Efficacy ranking based on SUCRA values was as follows: CHX (0.90), cetylpyridinium chloride (CPC) (0.68), herbal mouthwash (0.61), PVP-I (0.53), essential oil mouthwash (0.44), normal saline (0.42), hydrogen peroxide (0.39), and control (0.03).

CONCLUSIONS:

CHX appears to be the most effective mouthwash for reducing microbial aerosols, with CPC and herbal mouthwashes as viable alternatives, particularly for patients with CHX intolerance or mucosal sensitivity. However, evidence for CPC is limited, and the overall certainty is low. Further well-designed RCTs are needed, especially to evaluate efficacy against viral aerosols.

01 Jul 2026·JOURNAL OF EQUINE VETERINARY SCIENCE

Molecular typing, biofilm characteristics and biofilm-targeted inhibition strategies of Streptococcus equi subsp. zooepidemicus isolated from donkey endometritis

Article

Author: Wang, Z ; Wang, Y ; Bai, X ; Luo, T ; Zhu, Y ; Liu, B ; Wang, T ; Zheng, Y ; Wu, C ; Ma, S ; Li, J ; Qu, H ; Yu, J

BACKGROUND:

Endometritis is a major cause of infertility in intensively farmed donkeys. Streptococcus equi subsp. zooepidemicus (SEZ) is a predominant pathogen that readily forms biofilms in equine endometritis, conferring resistance to conventional treatments.

AIMS/OBJECTIVES:

This study aimed to characterize the biofilm dynamics of SEZ isolates obtained from donkeys and to evaluate potential anti-biofilm strategies with different drug combinations.

METHODS:

Uterine lavage samples were collected from 30 Dezhou Black donkeys with clinical endometritis. Bacterial cultures were performed on blood agar and MacConkey agar. SEZ isolates were identified by 16S rDNA PCR sequencing. Antimicrobial sensitivity test of SEZ isolates was performed with broth microdilution methods. Multilocus sequence typing (MLST) was used for strain characterization, and in vitro biofilm dynamics were assessed using crystal violet assays. Six agents-Tris-EDTA, hydrogen peroxide, DMSO, penicillin potassium, ceftiofur, and ciprofloxacin-were tested individually or in combination for their inhibitory effects on SEZ biofilms.

RESULTS:

Thirteen SEZ isolates were obtained from a total of 31 bacterial isolates (41.9%), representing four novel MLST types: STnovel, ST554, ST555 and ST556. Rapid formation of biofilm was observed at 12-24 h. Strain-dependent inhibitory patterns were observed in SEZ biofilms. Hydrogen peroxide showed the strongest inhibitory effect on STnovel biofilms (73.73 ± 1.48%), while ceftiofur-Tris-EDTA, ciprofloxacin-DMSO and penicillin-DMSO combinations exhibited the highest inhibition against ST554 (66.52 ± 3.66%), ST555 (82.60 ± 2.97%) and ST556 (83.35 ± 1.19%) biofilms.

CONCLUSION:

Strain-dependent inhibitory patterns were observed in SEZ biofilms. Antibiotic-non-antibiotic combinations showed promising effects in vitro, highlighting new therapeutic avenues for controlling SEZ biofilm-associated infections in donkeys.

01 Jun 2026·Food chemistry. Molecular sciences

Effects of hot water treatment, silver hydroxide ion solution and carboxymethyl chitosan on Lanxangia tsao-ko quality

Article

Author: Yang, Weize ; Yang, Tianmei ; Yang, Meiquan ; Zhang, Jinyu ; Zeng, Anqiong

The fruit of Lanxangia tsao - ko (LT), a widely used spice, is highly perishable during storage and transportation making it essential to develop effective preservation methods. This study employed multi-omics techniques to evaluate the effects of three different treatments on the quality of LT during short-term storage. Results demonstrated that, compared to the tap water control group (TW), the hot water treatment group (HW), carboxymethyl chitosan treatment group (CMC), and hydrogen peroxide‑silver ion solution treatment group (SP) significantly suppressed the increase in color change intensity (ΔE), browning index (BI), weight loss rate (W%), and rot rate (R%) of LT. Furthermore, these treatments promoted the accumulation of beneficial flavor substances, while reducing the level of unfavorable ones. Both CMC and SP were effective in inhibiting the increase of LT's respiration intensity and the relative abundance of pathogenic microorganisms like Rhizopus microsporus and Rhizopus arrhizus. However, HW led to an abnormal decrease in respiration intensity and increases the relative abundance of certain pathogenic microorganisms. In summary, although the temperature setting in the hot water treatment group was not ideal, hot water treatment still significantly inhibited the spoilage and discoloration phenomenon. Both CMC and SP can effectively extend the storage and transportation period of LT in all aspects. This study provides a new idea for the preservation of LT.

127

News (Medical) associated with Hydrogen Peroxide

22 May 2026

·www.globenewswire.com

Ebola Outbreak “Spreading at Alarming Speed,” WHO Warns — Growing Global Health Emergencies Highlight Rising Need for TOMI’s SteraMist Technology

Recent Ebola and Hantavirus Outbreaks Underscore Increasing Institutional Demand for Advanced Disinfection Solutions Across Hospitals, Hotels, Cruise Ships, Transportation Hubs, and Public FacilitiesFREDERICK, Md., May 22, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today highlighted the growing importance of advanced environmental disinfection solutions as global health officials raise alarms over the rapidly escalating Ebola outbreak in Central Africa. The World Health Organization (“WHO”) has stated they are “deeply concerned about the scale and speed of the epidemic” as the outbreak continues to expand across multiple regions. The outbreak, now classified as a Public Health Emergency of International Concern, reportedly involves more than 500 suspected cases and over 130 fatalities centered in the Democratic Republic of the Congo (“DRC”) and Uganda. WHO officials have also warned that the outbreak is expected to continue for months, raising concerns that strained healthcare systems, population displacement, and limited containment infrastructure could accelerate transmission risk. The outbreak involves the rare Bundibugyo strain of Ebola, a highly dangerous virus for which there is currently no broadly available approved vaccine, increasing urgency surrounding containment efforts and infection control preparedness. “As health authorities warn about the speed, scale, and expected duration of this Ebola outbreak, organizations around the world are being reminded that infectious disease preparedness is no longer optional,” said Dr. Halden Shane, CEO at TOMI Environmental Solutions. “Institutions are increasingly recognizing the need for scalable, rapid-response decontamination systems capable of addressing evolving biological threats.” TOMI has previously successfully helped contain an Ebola outbreak in West Africa. In collaboration with the WHO and supported by a USAID 'Fighting Ebola: A Grand Challenge for Development' grant, TOMI deployed SteraMist to help contain the spread of the virus. Teams utilized the system to secure high-risk "red zones" and safeguard healthcare personnel during the critical donning and doffing of protective gear. This application successfully prevented cross-contamination in the field, establishing SteraMist as a trusted partner in global health security. TOMI continues to support customers across healthcare, life sciences, hospitality, transportation, government, defense, and commercial sectors with technologies designed to help organizations rapidly respond to infectious disease threats and environmental contamination risks. For more information about SteraMist and TOMI Environmental Solutions, visit SteraMist.com. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the emergency sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT:John Nesbett/Zach NevasIMS Investor Relationstomi@imsinvestorrelations.com

Vaccine

19 May 2026

·www.globenewswire.com

TOMI™ Environmental Solutions Mobilizes SteraMist iHP Technology in Response to Emerging Global Pathogen Threats

Leveraging a Proven Legacy of Global Decontamination Leadership from the 2015 Ebola Response to Mitigate Emerging ThreatsFREDERICK, Md., May 19, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced the strategic mobilization of its SteraMist ionized Hydrogen Peroxide (iHP) technology in response to recent reported outbreaks of Ebola. Leveraging a proven history of rapid deployment during high-consequence biological events, TOMI is actively collaborating with Regional Emerging Special Pathogen Treatment Centers (RESPTCs) and specialized medical transportation groups to mitigate the risk of transmission. As health authorities monitor the escalation of this and other viral threats, the necessity for a validated, high-level disinfection protocol is paramount. TOMI’s expertise in managing viral hemorrhagic fevers is well-documented. During the 2015 Ebola outbreak, TOMI’s SteraMist iHP technology was instrumental in the decontamination of treatment units and transport vehicles, establishing the company as a trusted partner in global health security. Today, the company continues to support a nationwide network of RESPTCs, providing the essential infrastructure required to isolate and treat patients safely. “Our mission has always been to provide the ultimate device for infection control when the stakes are at their highest,” stated Dr. Halden Shane, CEO of TOMI Environmental Solutions. “By working alongside RESPTCs and specialized transport groups, we are ensuring that those on the front lines have access to the fastest and most effective decontamination technology available. Whether facing Ebola or other contagions, our SteraMist iHP decontamination technology is designed to neutralize the threat and restore safety to public and clinical spaces.” In addition to healthcare settings, TOMI is working closely with specialized transportation organizations that facilitate the movement of high-risk patients. SteraMist’s rapid turnaround time allows ambulances and aircraft to be decontaminated and returned to service in minutes, a vital factor during active outbreak responses where logistics and speed are essential to saving lives. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the emerging pathogen sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Zach Nevas IMS Investor Relations tomi@imsinvestorrelations.com

14 May 2026

·www.globenewswire.com

TOMI Environmental Solutions, Inc. Announces Second SteraMist Hybrid System Installation Contract with a World-Renowned East Coast Research University

FREDERICK, Md., May 14, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announce that we have been awarded the contract for a second installation of our SteraMist Hybrid System at a large historic prestigious research university on the East Coast. This new project will focus on the laboratory areas of the university, further enhancing their commitment to rigorous safety and sterilization protocols. Building on our successful prior collaboration with this university announced early January of this year, we will be working alongside familiar contractors to ensure a seamless integration of the SteraMist Hybrid System. We are excited to continue our partnership in delivering reliable decontamination solutions tailored to the university's highest specific needs. This installation represents yet another significant milestone in our integration pipeline, which has been a focal point of our communications. The successful deployment of the SteraMist Hybrid System in laboratory environments exemplifies our commitment to providing high-level, automated decontamination solutions that meet the stringent requirements of esteemed educational and research institutions. Elissa J. (E.J.) Shane, Chief Operating Officer of TOMI Environmental Solutions, stated, “We are thrilled to partner with this university once again as we expand our presence in their lab areas. The SteraMist Hybrid System continues to demonstrate its reliability and effectiveness in high-stakes environments, and we look forward to further supporting their operational needs through this installation.” This project not only highlights TOMI's ongoing dedication to excellence in disinfection technologies but also reinforces our position as a trusted partner in the healthcare and research sectors. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the laboratory market. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Zach NevasIMS Investor Relations tomi@imsinvestorrelations.com

100 Deals associated with Hydrogen Peroxide

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Keratosis, Seborrheic	United States	Aclaris Therapeutics, Inc.	14 Dec 2017
Disinfectants	Japan	Ebisu Yakuhin Kako KK	01 Mar 1986
Wound Infection	China	Tianjin Dongfang Guangcheng Pharmaceutical Chemical Co., Ltd.	01 Jan 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acne Vulgaris	Phase 3	United States	Aclaris Therapeutics, Inc.	17 Sep 2018
Plantar wart	Phase 3	United States	Aclaris Therapeutics, Inc.	13 Sep 2018
Locally Advanced Rectal Carcinoma	Phase 2	France	KORTUC, Inc.	01 Jul 2026
Breast cancer recurrent	Phase 2	India	KORTUC, Inc.	16 Jun 2020
Breast cancer recurrent	Phase 2	United Kingdom	KORTUC, Inc.	16 Jun 2020
Locally advanced breast cancer	Phase 2	India	KORTUC, Inc.	16 Jun 2020
Locally advanced breast cancer	Phase 2	United Kingdom	KORTUC, Inc.	16 Jun 2020
Dermatosis Papulosa Nigra	Phase 2	United States	Aclaris Therapeutics, Inc.	26 Jun 2017
Visible Lesion	Phase 2	United States	Aclaris Therapeutics, Inc.	26 Jun 2017
Locally Advanced Cervical Carcinoma	Phase 1	India	KORTUC, Inc.	01 Mar 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04659928 (CTgov)	Phase 4	COVID-19	41	High volume evacuation (HVE)+Hydrogen Peroxide (High Volume Evacuation (HVE) Suction Only and Hydrogen Peroxide)	uscekhwqmc(gfigdpzdxb) = mgwpzsecqm scanivyrrt (qpollgelrj, 16.38) View more	-	08 Jul 2025
				Extraoral vacuum aspirator (EVA)+Hydrogen Peroxide (HVE Suction and Extraoral Vacuum Aspirator (EVA) and Hydrogen Peroxide)	uscekhwqmc(gfigdpzdxb) = xpunoyukwq scanivyrrt (qpollgelrj, 155.43) View more
ASTRO2024	Not Applicable	Rectal Cancer	-	Hydrogen Peroxide + Neoadjuvant Chemoradiotherapy	imrcavkfzz(feudndnidq) = significantly more patients with grade 2 proctitis were observed in the IG (IG; 30%, HC; 0%; p<0.01) and 2 patients showed grade 2 hemorrhage in the IG but none in the HC qhrwlmpjui (ywbucjvrwk ) View more	-	01 Oct 2024
				Neoadjuvant Chemoradiotherapy
NCT03262701 (AHP, CTgov)	Phase 4	Chronic Periodontitis	42	Hydrogen Peroxide (Hydrogen Peroxide Gel for 13weeks)	zhazmkqvzz(zxeslbtwrm) = xefcvfqmoe dzlucnqlpt (zwpzmfwqge, 0.16) View more	-	21 Dec 2022
				Hydrogen Peroxide (Hydrogen Peroxide Gel for 26weeks)	zhazmkqvzz(zxeslbtwrm) = kqhjaygqib dzlucnqlpt (zwpzmfwqge, 0.05) View more
NCT03812510 (CTgov)	Phase 3	Warts	426	hydrogen peroxide (A-101 45% (Active))	oufpmhlfkf = iiwcjrxsum blgeicumqf (xslegprkfg, iyvcokqvot - wuvqdwvora) View more	-	23 Nov 2020
				isopropyl alcohol (Isopropyl Alcohol and Water (Vehicle))	oufpmhlfkf = uyhtdnhylq blgeicumqf (xslegprkfg, yvzcxuyzlx - opskasgloi) View more
NCT03687372 (CTgov)	Phase 3	Plantar wart \| Warts	503	vehicle	ruamracrib(xmlhsgbqng) = aycxcqtewc rtodoexdvw (okyycghqiq, oboearnlls - eqpfnxggvo) View more	-	05 Oct 2020
NCT03691831 (CTgov)	Phase 3	Plantar wart \| Warts	502	Active (Active)	zejbipyeal = jfmixzszvc jexdsncrtr (kcmecclmwj, vysyezmfpb - qpbwebpnsr) View more	-	05 Oct 2020
				Vehicle (Vehicle)	zejbipyeal = roicjbdajl jexdsncrtr (kcmecclmwj, fqoemecqod - wukholcqwe) View more
NCT03224598 (CTgov)	Phase 2	Dermatosis Papulosa Nigra	39	A-101 Topical Solution 40% (No Medical Abrading)	seaebgysim(ctwxnadyip) = yngueyoztt rmvylthvgu (kwcwvepebz, 0.52) View more	-	17 Mar 2020
				A-101 Topical Solution 40% (Medically Abrading)	seaebgysim(ctwxnadyip) = gjqrbbxnhm rmvylthvgu (kwcwvepebz, 0.90) View more
NCT03487588 (SK-FAN, CTgov)	Phase 4	Keratosis, Seborrheic	41	A-101 Topical Solution	weztdkbfip(wivfvcipsz) = lefwcqrehu qjohkajzgj (bocstlbahw, 0.62) View more	-	02 Oct 2019
NCT03148691 (CTgov)	Phase 2	Keratosis, Seborrheic	253	A-101 (Vehicle)	ebmjwfsbid(qnpeydyere) = faaojalvek selvzvlkcj (zucivzupbv, 10.4) View more	-	06 May 2019
				A-101 (A-101 Low Dose)	ebmjwfsbid(qnpeydyere) = hxlfzajzjh selvzvlkcj (zucivzupbv, 36.74) View more
NCT03210337 (CTgov)	Phase 2	Warts	157	A-101 Topical Solution (Active)	ciwgokfbvo(hynnvrkuxr) = keruxyzgzw vgevwxznak (ahghcewllf, 0.85) View more	-	01 May 2019
				A-101 Vehicle Solution (Vehicle)	ciwgokfbvo(hynnvrkuxr) = qrynojiheq vgevwxznak (ahghcewllf, 0.49) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Hydrogen Peroxide

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation